BRPI0409789A - vacina de tuberculose com eficácia aperfeiçoada - Google Patents

vacina de tuberculose com eficácia aperfeiçoada

Info

Publication number
BRPI0409789A
BRPI0409789A BRPI0409789-0A BRPI0409789A BRPI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid molecules
tuberculosis vaccine
relates
present
Prior art date
Application number
BRPI0409789-0A
Other languages
English (en)
Inventor
Leander Grode
Stefan H E Kaufmann
Borbel Raupach
Juergen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BRPI0409789A publication Critical patent/BRPI0409789A/pt
Publication of BRPI0409789B1 publication Critical patent/BRPI0409789B1/pt
Publication of BRPI0409789B8 publication Critical patent/BRPI0409789B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"VACINA DE TUBERCULOSE COM EFICáCIA APERFEIçOADA". A presente invenção refere-se a novas vacinas recombinantes provendo imunidade protetora contra tuberculose. Ainda, a presente invenção refere-se a novas moléculas de ácido nucléico recombinante, vetores contendo as ditas moléculas de ácido nucléico, células transformadas com as ditas moléculas de ácido nucléico e polipeptídeos codificados pelas ditas moléculas de ácido nucléico.
BRPI0409789A 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva BRPI0409789B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (3)

Publication Number Publication Date
BRPI0409789A true BRPI0409789A (pt) 2006-05-30
BRPI0409789B1 BRPI0409789B1 (pt) 2018-10-16
BRPI0409789B8 BRPI0409789B8 (pt) 2021-05-25

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409789A BRPI0409789B8 (pt) 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva

Country Status (24)

Country Link
US (2) US7988980B2 (pt)
EP (1) EP1618128B1 (pt)
JP (1) JP4662925B2 (pt)
KR (1) KR101101263B1 (pt)
CN (1) CN1798762B (pt)
AT (1) ATE473238T1 (pt)
AU (1) AU2004232485B2 (pt)
BR (1) BRPI0409789B8 (pt)
CA (1) CA2523084C (pt)
CU (1) CU23608A3 (pt)
CY (1) CY1110793T1 (pt)
DE (1) DE602004028000D1 (pt)
DK (1) DK1618128T3 (pt)
ES (1) ES2344698T3 (pt)
HK (1) HK1091217A1 (pt)
HR (1) HRP20100395T1 (pt)
MX (1) MXPA05011360A (pt)
PL (1) PL1618128T3 (pt)
PT (1) PT1618128E (pt)
RU (1) RU2342400C2 (pt)
SI (1) SI1618128T1 (pt)
UA (1) UA91180C2 (pt)
WO (1) WO2004094469A1 (pt)
ZA (1) ZA200508276B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1618128T3 (pl) * 2003-04-23 2010-12-31 Max Planck Gesellschaft Szczepionka przeciwko gruźlicy o ulepszonej skuteczności
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ZA200704765B (en) 2004-12-01 2008-09-25 Aeras Global Tb Vaccine Found Recombinant BCG strains with enhanced ability to escape the endosome
EP2244720A4 (en) * 2008-01-11 2013-01-16 Us Gov Health & Human Serv POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
SG188595A1 (en) * 2010-09-20 2013-04-30 Vakzine Projekt Man Gmbh Recombinant mycobacterium as vaccine for use in humans
US9187751B2 (en) 2010-11-10 2015-11-17 Laboratorios Leti, S.L. Adjuvant
MX345575B (es) * 2010-12-21 2017-02-03 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Micobacteria recombinante como vacuna.
PL2656070T3 (pl) 2010-12-21 2017-01-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oznaczanie skuteczności żywej rekombinowanej szczepionki anty-mykobakteryjnej
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110506108B (zh) * 2017-04-07 2023-10-24 成都安永鼎业生物技术有限公司 过表达phoP-phoR的重组BCG
WO2019021064A1 (en) * 2017-07-25 2019-01-31 Aurora Labs Ltd CONSTRUCTION OF SOFTWARE DELTA UPDATES FOR VEHICLE ECU SOFTWARE AND TOOL-BASED ANOMALY DETECTION
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4149529A1 (en) 2020-05-11 2023-03-22 Vakzine Projekt Management GmbH Prevention of infectious diseases by modulating the immune system
EP4373519A1 (en) 2021-07-22 2024-05-29 Serum Life Science Europe GmbH Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
PL1618128T3 (pl) * 2003-04-23 2010-12-31 Max Planck Gesellschaft Szczepionka przeciwko gruźlicy o ulepszonej skuteczności

Also Published As

Publication number Publication date
EP1618128B1 (en) 2010-07-07
HRP20100395T1 (hr) 2010-09-30
RU2005136354A (ru) 2006-03-20
CN1798762B (zh) 2010-04-28
US7988980B2 (en) 2011-08-02
AU2004232485B2 (en) 2009-11-26
AU2004232485A1 (en) 2004-11-04
RU2342400C2 (ru) 2008-12-27
WO2004094469A1 (en) 2004-11-04
KR20050114281A (ko) 2005-12-05
EP1618128A1 (en) 2006-01-25
ATE473238T1 (de) 2010-07-15
MXPA05011360A (es) 2005-11-28
CU23608A3 (es) 2010-12-08
SI1618128T1 (sl) 2010-11-30
CY1110793T1 (el) 2015-06-10
CN1798762A (zh) 2006-07-05
BRPI0409789B8 (pt) 2021-05-25
JP4662925B2 (ja) 2011-03-30
JP2007524367A (ja) 2007-08-30
CA2523084C (en) 2012-09-04
US20070134267A1 (en) 2007-06-14
KR101101263B1 (ko) 2012-01-04
DE602004028000D1 (de) 2010-08-19
UA91180C2 (ru) 2010-07-12
ZA200508276B (en) 2006-06-28
ES2344698T3 (es) 2010-09-03
BRPI0409789B1 (pt) 2018-10-16
DK1618128T3 (da) 2010-10-18
PL1618128T3 (pl) 2010-12-31
HK1091217A1 (en) 2007-01-12
US20120027794A1 (en) 2012-02-02
US8545854B2 (en) 2013-10-01
CA2523084A1 (en) 2004-11-04
PT1618128E (pt) 2010-10-13

Similar Documents

Publication Publication Date Title
BRPI0409789A (pt) vacina de tuberculose com eficácia aperfeiçoada
DE69836588D1 (de) Tuberkulose impfstoff
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
DE60126737D1 (de) Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
NZ598605A (en) Vaccine against african horse sickness virus
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
NZ603854A (en) West nile virus vaccine
DK1290160T3 (da) Humane Pellino-polypeptider
BR0313135A (pt) Epìtopos de células t em eritropoietina
BR0011469A (pt) Gm-csf equina
NO20051840L (no) IHNV G-protein til immunstimulering.
EA200401505A1 (ru) Экспрессия генов модифицированного вируса осповакцины ankara с использованием ati-промотора вируса коровьей оспы
WO2004067032A3 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
DK1740206T3 (da) PHEP, en aminosyrepermease af Staphylococcus Aureus
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE602005018369D1 (de) Neue proteine, z.b. zur verwendung für die in-vitro-isolierung und prävention von legionella pneumophila-infektionen
BR0013574A (pt) Antìgeno vacina de moraxella
DE60323678D1 (de) Kälteinduzierter expressionsvektor
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
GR1005595B (el) Εργαλειο μεταφορας ανοσομετατροπης μεσω διαμολυνσης του στοχου απο ιο φορεα και γονιδια για θεραπεια καρκινου
ITMI20041673A1 (it) Procedimento e stampo per produrre pali o simili, nonche' palo prodotto con tale procedimento e/o stampo
ITRM20020550A1 (it) Proteine mutanti dell'alfa-l-fucosidasi termofile e termostabili in grado di essere prodotte per via ricombinante.
TH94299B (th) สูตรผสมทางเภสัชกรรมซึ่งมีโปรตีน nma0939
CY1113678T1 (el) Νουλεοτιδικο εμβολιο

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF